For decades, researchers have wondered why some people with risky gene variants go on to develop Parkinson’s disease, while ...

A large longitudinal study found that pesticide exposure and caffeinated soda intake were linked to more severe motor ...

Psilocybin therapy improved cognitive performance, reduced mood dysfunction, motor, and nonmotor symptoms in patients with Parkinson disease.

Ventyx Biosciences has shared phase 2a data on a Parkinson’s disease prospect that has caught the eye of Sanofi. The readout shows the effect of VTX3232 on biomarkers, providing some of the data that ...

Known as much for their innovative videos and for their hits such as “Take on Me”, “Cry Wolf”, the band’s frontman shared ...

The University of California, San Francisco (UCSF) has received a $5 million donation from the Jean Pierre “JP” Conte Family ...

They were designed to treat diabetes, then prescribed for weight loss, and now—as researchers are finding—they might hold the ...

Basel: Roche has announced its decision to proceed with Phase III development of prasinezumab, an investigational ...

Cleveland Clinic Abu Dhabi, part of the M42 group, has successfully introduced continuous infusion therapy, a cutting-edge ...

Ventyx Biosciences disclosed positive top-line results from its Phase 2a study of VTX3232 in patients with early-stage Parkinson's disease.

Roche to advance prasinezumab into phase III development for early-stage Parkinson's disease: Basel Tuesday, June 17, 2025, 09:00 Hrs [IST] Roche announced its decision to proceed ...

Investing.com -- Ventyx Biosciences (NASDAQ: VTYX) stock was unchanged following the announcement of top-line data from its Phase 2a safety and biomarker trial evaluating VTX3232 in patients with ...